BIOTRICITY INC.
Close on Oct 19, 2026
- Market cap
- $1.15M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2026 Ended Dec 31, 2025 | Feb 18, 2026 | After market close | $4.00M | $-0.04 | – |
| Q2 FY2026 Ended Sep 30, 2025 | Nov 18, 2025 | After market close | – | – | – |
| Q3 FY2025 Ended Dec 31, 2024 | Feb 24, 2025 | After market close | $3.60M | $-0.05 | – |
| Q2 FY2025 Ended Sep 30, 2024 | Nov 20, 2024 | After market close | $3.30M | $-0.07 | – |
| Q1 FY2024 Ended Jun 30, 2023 | Jul 5, 2023 | After market close | $2.74M | $-0.09 | – |
| Q2 FY2023 Ended Sep 30, 2022 | Nov 18, 2022 | During market hours | – | – | – |
| Q4 FY2022 Ended Mar 31, 2022 | Jul 18, 2022 | After market close | – | – | – |
| Q3 FY2022 Ended Dec 31, 2021 | Feb 16, 2022 | After market close | – | – | – |
| Q2 FY2022 Ended Sep 30, 2021 | Nov 5, 2021 | After market close | – | – | – |
| Q1 FY2022 Ended Jun 30, 2021 | Jul 8, 2021 | After market close | – | – | – |
| Q4 FY2021 Ended Mar 31, 2021 | Apr 15, 2021 | During market hours | – | – | – |
| Q3 FY2021 Ended Dec 31, 2020 | Feb 12, 2021 | After market close | – | – | – |
Press releases
Announcements Biotricity filed with the SEC
Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue
Results of operations · EX-99.1 to Form 8-K
Strengthens Path to Scalable Profitability with Sustained Margins & Operational Efficiency in Second Quarter Fiscal 2026
Results of operations · EX-99.1 to Form 8-K
Delivers Record Margins, Record Revenues, and Record Cashflows with 21.7% Year-Over-Year Sales Growth for its Third Quarter of Fiscal
Results of operations · EX-99.1 to Form 8-K
Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025
Results of operations · EX-99.1 to Form 8-K
Reports Strong Growth for its First Quarter Fiscal Year 2024 and Provides Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Reports Business Update, Financial Results for Q4 and Full Year FY23; Company Posts Robust Revenue Growth, Overall Higher Margins, with
Results of operations · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
Reports Financial Results for Fiscal 2023 Second Quarter
Results of operations · EX-99.1 to Form 8-K
Reports Financial Results for Fiscal 2023 First Quarter
Results of operations · EX-99.1 to Form 8-K
Reports Financial Results for Fiscal 2022 Fourth Quarter and Full Year
Results of operations · EX-99.1 to Form 8-K
to host investor call on Tuesday February 15th at 4:15 pm ET
Results of operations · EX-99.1 to Form 8-K
in Remote Cardiac Health Monitoring Solutions, Biotricity CEO
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Company reports tenth consecutive quarter of triple-digit year-over-year revenue growth
Results of operations · EX-99.1 to Form 8-K